These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2112554)

  • 1. Use of buserelin in an IVF programme for pituitary-ovarian suppression prior to ovarian stimulation with exogenous gonadotrophins.
    Ibrahim ZH; Matson PL; Buck P; Critchlow JD; Newman MC; Horne G; Hughes S; Lieberman BA
    Hum Reprod; 1990 Apr; 5(3):258-62. PubMed ID: 2112554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum inhibin as an index of ovarian function in women undergoing pituitary suppression and ovarian stimulation in an in vitro fertilization program.
    Matson PL; Morris ID; Sun JG; Ibrahim ZH; Lieberman BA
    Horm Res; 1991; 35(5):173-7. PubMed ID: 1802818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.
    Smith EM; Anthony FW; Gadd SC; Masson GM
    BMJ; 1989 Jun; 298(6686):1483-6. PubMed ID: 2503080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure to improve ovarian response by combined gonadotropin-releasing hormone agonist and gonadotropin therapy.
    Bider D; Kokia E; Lipitz S; Blankstein J; Mashiach S; Serr DM; Ben-Rafael Z
    Gynecol Obstet Invest; 1990; 29(3):192-6. PubMed ID: 2113505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols.
    Lipitz S; Ben-Rafael Z; Dor J; Shalev J; Elenbogen A; Levran D; Serr DM; Mashiach S
    Gynecol Obstet Invest; 1989; 28(1):31-4. PubMed ID: 2528497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins.
    Wildt L; Diedrich K; van der Ven H; al Hasani S; Hübner H; Klasen R
    Hum Reprod; 1986 Jan; 1(1):15-9. PubMed ID: 2971082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment.
    Engmann L; Sladkevicius P; Agrawal R; Bekir JS; Campbell S; Tan SL
    Fertil Steril; 1999 Jan; 71(1):22-9. PubMed ID: 9935111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study.
    Tapanainen J; Hovatta O; Juntunen K; Martikainen H; Ratsula K; Tulppala M; Tuomivaara L
    Hum Reprod; 1993 Dec; 8(12):2052-5. PubMed ID: 8150902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?
    Wada I; Matson PL; Horne G; Buck P; Lieberman BA
    Hum Reprod; 1992 Sep; 7(8):1090-3. PubMed ID: 1400932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertilization in vitro of supernumerary oocytes following gamete intra-fallopian transfer (GIFT).
    Critchlow JD; Matson PL; Troup SA; Ibrahim ZH; Burslem RW; Buck P; Lieberman BA
    Hum Reprod; 1990 Oct; 5(7):853-6. PubMed ID: 2125057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent elevation of serum oestradiol levels by functional ovarian cysts despite effective pituitary desensitization with GnRH agonists.
    Jenkins JM; Anthony FW; Lee A; Masson GM; Thomas E
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):357-9. PubMed ID: 8187299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine changes in women conceiving during treatment with an LHRH agonist.
    Isherwood PJ; Ibrahim ZH; Matson PL; Morroll DR; Burslem RW; Lieberman BA
    Hum Reprod; 1990 May; 5(4):409-12. PubMed ID: 2113928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization.
    MacLachlan V; Besanko M; O'Shea F; Wade H; Wood C; Trounson A; Healy DL
    N Engl J Med; 1989 May; 320(19):1233-7. PubMed ID: 2496310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine responses to gonadotrophins after LHRH agonist administration on cycle days 1-4: prevention of premature luteinization.
    Martikainen H; Rönnberg L; Tapanainen J; Puistola U; Orava M; Kauppila A
    Hum Reprod; 1990 Apr; 5(3):246-9. PubMed ID: 2112552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal and histological evaluation of the luteal phase after combined GnRH-agonist/gonadotrophin treatment for superovulation and luteal phase support in in-vitro fertilization.
    Balasch J; Jové I; Márquez M; Vanrell JA
    Hum Reprod; 1991 Aug; 6(7):914-7. PubMed ID: 1761657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
    Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
    Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term use of buserelin in combination with human menopausal gonadotrophins for ovarian stimulation for in-vitro fertilization in endocrinologically normal women.
    Smitz J; Bollen N; Camus M; Devroey P; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1990 Feb; 5(2):157-62. PubMed ID: 2108989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.